Retrospective 7,713 COVID-19 patients in Korea, showing no significant difference in mortality with paracetamol use.
Paracetamol is also known as acetaminophen, Tylenol, Panadol, Calpol, Tempra, Calprofen, Doliprane, Efferalgan, Grippostad C, Dolo, Acamol, Fevadol, Crocin, and Perfalgan.
|
risk of death, 1.9% lower, RR 0.98, p = 0.97, treatment 58, control 7,655, adjusted per study, odds ratio converted to relative risk, multivariable, control prevalance approximated with overall prevalence.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Oh et al., 24 Jun 2021, retrospective, South Korea, peer-reviewed, 5 authors, study period 1 January, 2020 - 4 June, 2020.
Contact:
uchic@ncc.re.kr (corresponding author), airohtak@hotmail.com, songoficu@outlook.kr, leejoon.com@gmail.com, ytjeon@snubh.org.
Musculoskeletal Disorders, Pain Medication, and in-Hospital Mortality among Patients with COVID-19 in South Korea: A Population-Based Cohort Study
Tak-Kyu Oh, In-Ae Song, Joon Lee, Woosik Eom, Young-Tae Jeon
International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18136804
We aimed to investigate whether comorbid musculoskeletal disorders (MSD)s and pain medication use was associated with in-hospital mortality among patients with coronavirus disease 2019 . Adult patients (≥20 years old) with a positive COVID-19 diagnosis until 5 June 2020 were included in this study, based on the National Health Insurance COVID-19 database in South Korea. MSDs included osteoarthritis, neck pain, lower back pain, rheumatoid arthritis, and others, while pain medication included paracetamol, gabapentin, pregabalin, glucocorticoid, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids (strong and weak opioids), and benzodiazepine. Primary endpoint was in-hospital mortality. A total of 7713 patients with COVID-19 were included, and in-hospital mortality was observed in 248 (3.2%) patients. In multivariate logistic regression analysis, no MSDs (p > 0.05) were significantly associated with in-hospital mortality. However, in-hospital mortality was 12.73 times higher in users of strong opioids (odds ratio: 12.73, 95% confidence interval: 2.44-16.64; p = 0.002), while use of paracetamol (p = 0.973), gabapentin or pregabalin (p = 0.424), glucocorticoid (p = 0.673), NSAIDs (p = 0.979), weak opioids (p = 0.876), and benzodiazepine (p = 0.324) was not associated with in-hospital mortality. In South Korea, underlying MSDs were not associated with increased in-hospital mortality among patients with COVID-19. However, use of strong opioids was significantly associated with increased in-hospital mortality among the patients.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/ijerph18136804/s1, Table S1 : ICD-10 codes and Table S2 : The ICD-10 codes used by comorbidity to compute the Charlson comorbidity index. Informed Consent Statement: Informed consent was waived by the IRB, as the analyses were performed retrospectively using anonymized data derived from the South Korean NHIS database.
Conflicts of Interest: The authors declare no conflict of interest.
References
Briggs, Woolf, Dreinhöfer, Homb, Hoy et al., Reducing the global burden of musculoskeletal conditions, Bull. World Heal. Organ,
doi:10.2471/BLT.17.204891Dagan, Barda, Kepten, Miron, Perchik et al., BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, N. Engl. J. Med,
doi:10.1056/NEJMoa2101765Diasso, Birke, Nielsen, Main, Højsted et al., The effects of long-term opioid treatment on the immune system in chronic non-cancer pain patients: A systematic review, Eur. J. Pain,
doi:10.1002/ejp.1506Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies, Ann. Intern. Med,
doi:10.7326/0003-4819-147-8-200710160-00010Flint, Janowitz, Connell, Roberts, Denton et al., Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity, Cell Metab,
doi:10.1016/j.cmet.2016.10.010Fredi, Cavazzana, Moschetti, Andreoli, Franceschini et al., COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study, Lancet Rheumatol,
doi:10.1016/S2665-9913(20)30169-7Generaal, Vogelzangs, Macfarlane, Geenen, Smit et al., Basal inflammation and innate immune response in chronic multisite musculoskeletal pain, Pain,
doi:10.1016/j.pain.2014.05.007Greenland, Mansournia, Altman, Sparse data bias: A problem hiding in plain sight, BMJ,
doi:10.1136/bmj.i1981Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in Immune-Mediated Inflammatory Diseases-Case Series from New York, N. Engl. J. Med,
doi:10.1056/NEJMc2009567Haberman, Castillo, Chen, Yan, Ramirez et al., COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes, Arthritis Rheumatol,
doi:10.1002/art.41456Kim, Fine, Li, Kimmel, Ngo et al., Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study, PLoS Med,
doi:10.1371/journal.pmed.1003247Mackinnon, Socías, Bardwell, COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings, J. Subst. Abus Treat,
doi:10.1016/j.jsat.2020.108153Manuel, Estabrook, The American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, Clin. Transplant,
doi:10.1111/ctr.13511Oh, Jeon, Choi, Trends in chronic opioid use and association with five-year survival in South Korea: A populationbased cohort study, Br. J. Anaesth,
doi:10.1016/j.bja.2019.08.012Oh, Song, Trends in long-term glucocorticoid use and risk of 5-year mortality: A historical cohort study in South Korea, Endocrine,
doi:10.1007/s12020-020-02382-6Pereira, Lawlor, Vigano, Dorgan, Bruera, Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing, J. Pain Symptom Manag,
doi:10.1016/S0885-3924(01)00294-9Pierce, Bird, Hickman, Millar, National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005-2009, Drug Alcohol Depend,
doi:10.1016/j.drugalcdep.2014.09.782Ray, Chung, Murray, Hall, Stein, Prescription of Long-Acting Opioids and Mortality in Patients with Chronic Noncancer Pain, JAMA,
doi:10.1001/jama.2016.7789Schwetz, Calder, Rosenthal, Kattakuzhy, Fauci, Opioids and Infectious Diseases: A Converging Public Health Crisis, J. Infect. Dis,
doi:10.1093/infdis/jiz133Shah, Kuo, Baillargeon, Raji, The impact of long-term opioid use on the risk and severity of COVID-19, J. Opioid Manag,
doi:10.5055/jom.2020.0597Waghmare, Englund, Boeckh, How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation, Blood,
doi:10.1182/blood-2016-01-634873Wang, Kaelber, Xu, Volkow, COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States, Mol. Psychiatry,
doi:10.1038/s41380-020-00880-7Weisberg, Gordon, Barry, Becker, Crystal et al., Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients, J. Acquir. Immune Defic. Syndr,
doi:10.1097/QAI.0000000000000591Wilson, Ramage, Fagan, A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder, J. Rural. Heal,
doi:10.1111/jrh.12438Wolfe, Caplan, Michaud, Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy, Arthritis Rheum,
doi:10.1002/art.21568
